{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:10:53Z","timestamp":1791447053937,"version":"4.3.3"},"reference-count":236,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T00:00:00Z","timestamp":1560556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011039","name":"Swiss Centre for Applied Human Toxicology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011039","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.phrs.2019.104311","type":"journal-article","created":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T10:34:28Z","timestamp":1560594868000},"page":"104311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Drug-induced endocrine blood pressure elevation"],"prefix":"10.1016","volume":"154","author":[{"given":"Katharina R.","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"George R.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Odermatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.phrs.2019.104311_bib0005","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/eurheartj\/eht534","article-title":"Secondary arterial hypertension: when, who, and how to screen?","volume":"35","author":"Rimoldi","year":"2014","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.phrs.2019.104311_bib0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1210\/er.2017-00054","article-title":"Screening for endocrine hypertension: an endocrine society scientific statement","volume":"38","author":"Young","year":"2017","journal-title":"Endocr. Rev."},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0015","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib0020","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2019.104311_bib0025","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/bs.vh.2018.10.006","article-title":"Primary aldosteronism: present and future","volume":"109","author":"Funder","year":"2019","journal-title":"Vitam. Horm."},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib0030","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Pt A","key":"10.1016\/j.phrs.2019.104311_bib0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejphar.2015.06.027","article-title":"Drug induced hypertension--An unappreciated cause of secondary hypertension","volume":"763","author":"Grossman","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104311_bib0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40292-014-0038-3","article-title":"Italian Society of, Clinical management of drug-induced hypertension: 2013 Practical Recommendations of the Italian Society of Hypertension (SIIA)","volume":"21","author":"Virdis","year":"2014","journal-title":"High Blood Press. Cardiovasc. Prev."},{"issue":"9349","key":"10.1016\/j.phrs.2019.104311_bib0045","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0050","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11906-017-0736-z","article-title":"Drug-induced hypertension: focus on mechanisms and management","volume":"19","author":"Lovell","year":"2017","journal-title":"Curr. Hypertens. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2019.104311_bib0055","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0272-0590(84)90224-0","article-title":"The effects of drugs and chemicals upon the structure of the adrenal gland","volume":"4","author":"Ribelin","year":"1984","journal-title":"Fundam. Appl. Toxicol."},{"issue":"Pt B","key":"10.1016\/j.phrs.2019.104311_bib0060","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jsbmb.2014.10.009","article-title":"Adrenocortical endocrine disruption","volume":"155","author":"Harvey","year":"2016","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"FR 54295","key":"10.1016\/j.phrs.2019.104311_bib0065","first-page":"54295","article-title":"Food and drug administration, nonclinical evaluation of endocrine-related drug toxicity - guidance for industry","volume":"80","year":"2015","journal-title":"Fed. Regist."},{"issue":"2","key":"10.1016\/j.phrs.2019.104311_bib0070","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1210\/me.2012-1287","article-title":"Structural insights into aldosterone synthase substrate specificity and targeted inhibition","volume":"27","author":"Strushkevich","year":"2013","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.phrs.2019.104311_bib0075","series-title":"Chapter 2, Syndromes of Mineralocorticoid Excess Endocrine Hypertension: Underlying Mechanisms and Therapy, Contemporary Endocrinology","first-page":"33","author":"Eugen Melcescu","year":"2013"},{"issue":"1","key":"10.1016\/j.phrs.2019.104311_bib0080","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1210\/er.2010-0013","article-title":"The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders","volume":"32","author":"Miller","year":"2011","journal-title":"Endocr. Rev."},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0085","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1210\/jcem-51-5-1085","article-title":"Deoxycorticosterone and aldosterone clearance and binding in normal and hypertensive man","volume":"51","author":"Zipser","year":"1980","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2019.104311_bib0090","article-title":"Mineralocorticoid hypertension and hypokalaemia induced by posaconazole","volume":"2018","author":"Boughton","year":"2018","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"10.1016\/j.phrs.2019.104311_bib0095","first-page":"1","article-title":"Posaconazole-induced hypertension and hypokalemia due to inhibition of the 11beta-hydroxylase enzyme","author":"Barton","year":"2018","journal-title":"Clinical Kideny Journal"},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib0100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ancard.2014.05.007","article-title":"[Itraconazole: a new drug-related cause of hypertension]","volume":"63","author":"Denolle","year":"2014","journal-title":"Ann. Cardiol. Angeiol. (Paris)"},{"key":"10.1016\/j.phrs.2019.104311_bib0105","doi-asserted-by":"crossref","DOI":"10.1111\/myc.12749","article-title":"3rd, Itraconazole induced hypertension and hypokalemia: mechanistic evaluation","author":"Hoffmann","year":"2018","journal-title":"Mycoses"},{"issue":"8","key":"10.1016\/j.phrs.2019.104311_bib0110","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00760-17","article-title":"In vivo 11beta-Hydroxysteroid dehydrogenase inhibition in posaconazole-induced hypertension and hypokalemia","volume":"61","author":"Thompson","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0115","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00019-17","article-title":"Hypokalemia and hypertension associated with supratherapeutic posaconazole levels","volume":"61","author":"Mahmood","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.phrs.2019.104311_bib0120","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02605-17","article-title":"Refractory hypokalemia from syndrome of apparent mineralocorticoid excess on low-dose posaconazole","author":"Wassermann","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.phrs.2019.104311_bib0125","series-title":"Posaconazole-Induced Pseudohyperaldosteronism, Antimicrobial Agents and Chemotherapy","author":"Kuriakose","year":"2018"},{"key":"10.1016\/j.phrs.2019.104311_bib0130","doi-asserted-by":"crossref","DOI":"10.1210\/js.2019-00189","article-title":"Posaconazole-induced hypertension due to inhibition of 11\u03b2-hydroxylase and 11\u03b2-hydroxysteroid dehydrogenase 2","author":"Thompson","year":"2019","journal-title":"J. Endocr. Soc."},{"issue":"10","key":"10.1016\/j.phrs.2019.104311_bib0135","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/dmd.104.000315","article-title":"Role of itraconazole metabolites in CYP3A4 inhibition","volume":"32","author":"Isoherranen","year":"2004","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0140","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ejps.2004.01.005","article-title":"Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study","volume":"21","author":"Wexler","year":"2004","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.phrs.2019.104311_bib0145","series-title":"Janssen-Cilag-AG, Sporanox Drug Safety Sheet","year":"2015"},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib0150","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1124\/dmd.115.067744","article-title":"Evaluation of ketoconazole and its alternative clinical CYP3A4\/5 inhibitors as inhibitors of drug transporters: the in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters","volume":"44","author":"Vermeer","year":"2016","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"10.1016\/j.phrs.2019.104311_bib0155","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1021\/jm00194a023","article-title":"Antimycotic imidazoles. Part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent","volume":"22","author":"Heeres","year":"1979","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0160","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/clinids\/2.4.674","article-title":"An evaluation of two years of clinical experience with ketoconazole","volume":"2","author":"Symoens","year":"1980","journal-title":"Rev. Infect. Dis."},{"issue":"12","key":"10.1016\/j.phrs.2019.104311_bib0165","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/archinte.1982.00340250097015","article-title":"Ketoconazole blocks testosterone synthesis","volume":"142","author":"Pont","year":"1982","journal-title":"Arch. Intern. Med."},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0170","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1210\/jcem-57-4-732","article-title":"Site of action of low dose ketoconazole on androgen biosynthesis in men","volume":"57","author":"Santen","year":"1983","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib0175","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.19.6.1073","article-title":"Gynecomastia with ketoconazole","volume":"19","author":"DeFelice","year":"1981","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib0180","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-97-3-370","article-title":"Ketoconazole blocks adrenal steroid synthesis","volume":"97","author":"Pont","year":"1982","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.phrs.2019.104311_bib0185","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2265.1991.tb03516.x","article-title":"The influence of ketoconazole on human adrenal steroidogenesis: incubation studies with tissue slices","volume":"35","author":"Engelhardt","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0190","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1210\/edrv-7-4-409","article-title":"Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis","volume":"7","author":"Feldman","year":"1986","journal-title":"Endocr. Rev."},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0195","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1172\/JCI110903","article-title":"Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes","volume":"71","author":"Loose","year":"1983","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib0200","doi-asserted-by":"crossref","first-page":"R263","DOI":"10.1530\/EJE-14-1014","article-title":"Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing\u2019s syndrome","volume":"172","author":"Daniel","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.phrs.2019.104311_bib0205","series-title":"European Medicines Agency - Committee for Medicinal Products for Human Use (CHMP), Assessment Report: Ketoconazole HRA, Procedure No. EMEA\/H\/C\/003906\/0000","year":"2014"},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0210","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in Cushing\u2019s disease: is it worth a try?","volume":"99","author":"Castinetti","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib0215","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.1097\/00004872-198900076-00102","article-title":"Arterial hypertension as a complication of prolonged ketoconazole treatment","volume":"7","author":"Leal-Cerro","year":"1989","journal-title":"J. Hypertens. Suppl."},{"issue":"8559","key":"10.1016\/j.phrs.2019.104311_bib0220","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(87)93039-X","article-title":"Hypertension during high-dose ketoconazole treatment: a probable mineralocorticosteroid effect","volume":"2","author":"Aabo","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.104311_bib0225","series-title":"European Medicines Agency, Suspension of Marketing Authorisations for Oral Ketoconazole. Benefit of Oral Ketoconazole Does Not Outweigh Risk of Liver Injury in Fungal Infections","year":"2013"},{"key":"10.1016\/j.phrs.2019.104311_bib0230","series-title":"FDA Drug Safety Communication: FDA Limits Usage of Nizoral (ketoconazole) Oral Tablets Due to Potentially Fatal Liver Injury and Risk of Drug Interactions and Adrenal Gland Problems","year":"2013"},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib0235","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11102-016-0742-1","article-title":"Updates on the role of adrenal steroidogenesis inhibitors in Cushing\u2019s syndrome: a focus on novel therapies","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.phrs.2019.104311_bib0240","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1530\/JOE-14-0300","article-title":"Treatment of Cushing\u2019s disease: a mechanistic update","volume":"223","author":"Cuevas-Ramos","year":"2014","journal-title":"J. Endocrinol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0245","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0022-4731(74)90051-X","article-title":"Modifiers of steroid-hormone metabolism: a review of their chemistry, biochemistry and clinical applications","volume":"5","author":"Gower","year":"1974","journal-title":"J. Steroid Biochem."},{"issue":"8","key":"10.1016\/j.phrs.2019.104311_bib0250","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1210\/jcem-18-8-906","article-title":"Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11 beta-hydroxylation","volume":"18","author":"Liddle","year":"1958","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2019.104311_bib0255","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2265.1991.tb03517.x","article-title":"Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing\u2019s syndrome","volume":"35","author":"Verhelst","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0260","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/00325481.1969.11697308","article-title":"The metyrapone test of pituitary function","volume":"46","author":"Doe","year":"1969","journal-title":"Postgrad. Med."},{"issue":"1","key":"10.1016\/j.phrs.2019.104311_bib0265","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2265.1981.tb00362.x","article-title":"Clinical response to metyrapone as indicated by measurement of mineralocorticoids and glucocorticoids in normal children","volume":"14","author":"Sonino","year":"1981","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.phrs.2019.104311_bib0270","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0889-8529(05)70064-5","article-title":"Medical therapy for Cushing\u2019s disease","volume":"28","author":"Sonino","year":"1999","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"1","key":"10.1016\/j.phrs.2019.104311_bib0275","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1210\/jcem-29-1-6","article-title":"Plasma 11-deoxycorticosteroid and ACTH response to metyrapone (plasma metyrapone test)","volume":"29","author":"Strott","year":"1969","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2019.104311_bib0280","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1210\/jcem-19-8-875","article-title":"Clinical application of a new test of pituitary reserve","volume":"19","author":"Liddle","year":"1959","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Pt 5","key":"10.1016\/j.phrs.2019.104311_bib0285","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1258\/acb.2011.011014","article-title":"Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11beta-hydroxylase inhibitor metyrapone","volume":"48","author":"Monaghan","year":"2011","journal-title":"Ann. Clin. Biochem."},{"issue":"18","key":"10.1016\/j.phrs.2019.104311_bib0290","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0295","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.phrs.2019.104311_bib0300","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/HJH.0b013e328363570c","article-title":"Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy","volume":"31","author":"Schumacher","year":"2013","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2019.104311_bib0305","series-title":"U.S. National Library of Medicine, ClinicalTrials.gOv - Efficacy and Safety Evaluation of Osilodrostat in Cushing\u2019s Disease (LINC-4), NCT02697734","year":"2019"},{"issue":"2","key":"10.1016\/j.phrs.2019.104311_bib0310","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","article-title":"Osilodrostat, a potent oral 11beta-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing\u2019s disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0315","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1210\/jc.2013-2117","article-title":"LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing\u2019s disease: results from a multicenter, proof-of-concept study","volume":"99","author":"Bertagna","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2019.104311_bib0320","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","article-title":"Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2)","volume":"69","author":"Bogman","year":"2017","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib0325","article-title":"LY3045697: results from two randomized clinical trials of a novel inhibitor of aldosterone synthase","volume":"18","author":"Sloan-Lancaster","year":"2017","journal-title":"J. Renin. Syst."},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0330","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1055\/s-2004-861545","article-title":"Overview of dehydroepiandrosterone biosynthesis","volume":"22","author":"Auchus","year":"2004","journal-title":"Semin. Reprod. Med."},{"issue":"13","key":"10.1016\/j.phrs.2019.104311_bib0335","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1021\/jm00013a022","article-title":"Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer","volume":"38","author":"Potter","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104311_bib0340","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/DDDT.S15850","article-title":"Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer","volume":"6","author":"Rehman","year":"2012","journal-title":"Drug Des. Devel. Ther."},{"issue":"28","key":"10.1016\/j.phrs.2019.104311_bib0345","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104311_bib0350","first-page":"1","article-title":"Abiraterone and spironolactone in prostate cancer: a combination to avoid","author":"Dhondt","year":"2018","journal-title":"Acta Clin. Belg."},{"key":"10.1016\/j.phrs.2019.104311_bib0355","series-title":"INN-abiraterone, Summary of Product Characteristics, European Medicines Agency, 13\/03\/2019","author":"Zytiga","year":"2019"},{"issue":"9","key":"10.1016\/j.phrs.2019.104311_bib0360","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1158\/0008-5472.CAN-11-3980","article-title":"Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100","volume":"72","author":"Richards","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2019.104311_bib0365","series-title":"Takeda, Oncology, Takeda Announces Termination of Orteronel (TAK-700) Development for Prostate Cancer in Japan, U.S.A. and Europe","year":"2014"},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0370","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1758834016642370","article-title":"CYP17 inhibitors in prostate cancer: latest evidence and clinical potential","volume":"8","author":"Alex","year":"2016","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.phrs.2019.104311_bib0375","series-title":"U.S. National Library of Medicina, ClinicalTrials.gov, A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer","year":"2019"},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib0380","first-page":"278","article-title":"Anabolic steroids in the UK: an increasing issue for public health, Drugs: education","volume":"24","author":"McVeigh","year":"2017","journal-title":"Health Promot. Chronic Dis. Prev. Can."},{"issue":"11","key":"10.1016\/j.phrs.2019.104311_bib0385","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJM199603143341107","article-title":"Androgens in men--uses and abuses","volume":"334","author":"Bagatell","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0390","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1249\/01.mss.0000210194.56834.5d","article-title":"Anabolic androgenic steroids: a survey of 500 users","volume":"38","author":"Parkinson","year":"2006","journal-title":"Med. Sci. Sports Exerc."},{"issue":"2","key":"10.1016\/j.phrs.2019.104311_bib0395","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1210\/edrv-9-2-181","article-title":"Androgen abuse by athletes","volume":"9","author":"Wilson","year":"1988","journal-title":"Endocr. Rev."},{"issue":"8","key":"10.1016\/j.phrs.2019.104311_bib0400","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2165\/00007256-200434080-00003","article-title":"Effects of androgenic-anabolic steroids in athletes","volume":"34","author":"Hartgens","year":"2004","journal-title":"Sports Med."},{"issue":"1","key":"10.1016\/j.phrs.2019.104311_bib0405","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.yrtph.2010.02.001","article-title":"Adverse health effects of anabolic-androgenic steroids","volume":"57","author":"van Amsterdam","year":"2010","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib0410","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.amjcard.2010.05.013","article-title":"Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm","volume":"106","author":"Achar","year":"2010","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib0415","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/HYPERTENSIONAHA.112.195149","article-title":"Testosterone and secondary hypertension: new pieces to the puzzle","volume":"59","author":"Barton","year":"2012","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib0420","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0015-0282(16)43869-0","article-title":"Endocrine properties and clinical application of danazol","volume":"31","author":"Dmowski","year":"1979","journal-title":"Fertil. Steril."},{"issue":"12","key":"10.1016\/j.phrs.2019.104311_bib0425","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1701-2163(16)30075-5","article-title":"Vaginally Administered Danazol: An Overlooked Option in the Treatment of Rectovaginal Endometriosis?","volume":"37","author":"Godin","year":"2015","journal-title":"J. Obstet. Gynaecol. Can."},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib0430","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/humrep\/det457","article-title":"European Society of Human, Embryology, ESHRE guideline: management of women with endometriosis","volume":"29","author":"Dunselman","year":"2014","journal-title":"Hum. Reprod."},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0435","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1586\/17474086.2015.1073105","article-title":"Current treatment strategies in autoimmune hemolytic disorders","volume":"8","author":"Barcellini","year":"2015","journal-title":"Expert Rev. Hematol."},{"issue":"11","key":"10.1016\/j.phrs.2019.104311_bib0440","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1056\/NEJMc1607752","article-title":"Danazol treatment for telomere diseases","volume":"375","author":"Townsley","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104311_bib0445","series-title":"Sanofi-aventis U.S. LLC, DANOCRINE\u00ae Drug Safety Sheet","year":"2011"},{"issue":"10","key":"10.1016\/j.phrs.2019.104311_bib0450","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/archinte.1980.00330210127038","article-title":"Hypertension: a complication of danazol therapy","volume":"140","author":"Bretza","year":"1980","journal-title":"Arch. Intern. Med."},{"issue":"8","key":"10.1016\/j.phrs.2019.104311_bib0455","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0015-0282(16)42732-9","article-title":"Danazol inhibits steroidogenesis","volume":"28","author":"Barbieri","year":"1977","journal-title":"Fertil. Steril."},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib0460","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0039-128X(80)90038-0","article-title":"Danazol inhibits human adrenal 21-and 11 beta-hydroxylation in vitro","volume":"35","author":"Barbieri","year":"1980","journal-title":"Steroids"},{"issue":"1-2","key":"10.1016\/j.phrs.2019.104311_bib0465","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0028-2243(86)90108-5","article-title":"Endocrine consequences of danazol treatment in menorrhagia","volume":"23","author":"Guoth","year":"1986","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104311_bib0470","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0022-4731(85)90243-2","article-title":"A simple in vitro approach to the estimation of the biopotency of drugs affecting adrenal steroidogenesis","volume":"23","author":"Lambert","year":"1985","journal-title":"J. Steroid Biochem."},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib0475","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1507\/endocrj.40.659","article-title":"Adrenal steroids in serum during danazol therapy, taking into account cross-reactions between danazol metabolites and serum androgens","volume":"40","author":"Murakami","year":"1993","journal-title":"Endocr. J."},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0480","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0015-0282(16)44657-1","article-title":"Inhibition of adrenal steroidogenesis by danazol in vivo","volume":"33","author":"Stillman","year":"1980","journal-title":"Fertil. Steril."},{"issue":"11","key":"10.1016\/j.phrs.2019.104311_bib0485","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/j.1398-9995.2007.01477.x","article-title":"Lack of dehydroepiandrosterone in type I and II hereditary angioedema and role of danazol in steroid hormone conversion","volume":"62","author":"Thon","year":"2007","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.phrs.2019.104311_bib0490","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0015-0282(16)41479-2","article-title":"Adrenal function during chronic danazol administration","volume":"26","author":"Wentz","year":"1975","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.phrs.2019.104311_bib0495","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/00016348409156998","article-title":"Peripheral levels of dehydroepiandrosterone sulfate, dehydroepiandrosterone, androstenedione, and testosterone following different doses of danazol","volume":"123","author":"Carlstrom","year":"1984","journal-title":"Acta Obstet. Gynecol. Scand. Suppl."},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0500","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0015-0282(16)46940-2","article-title":"Peripheral androgen levels in danazol-treated premenopausal women","volume":"39","author":"Carlstrom","year":"1983","journal-title":"Fertil. Steril."},{"issue":"2","key":"10.1016\/j.phrs.2019.104311_bib0505","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/toxsci\/kfs022","article-title":"The anabolic androgenic steroid fluoxymesterone inhibits 11beta-hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation","volume":"126","author":"Furstenberger","year":"2012","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.phrs.2019.104311_bib0510","series-title":"Aspen Pharma, Deca-durabolin Drug Safety Sheet","year":"2018"},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0515","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1742-7843.2009.00439.x","article-title":"Impact of nandrolone decanoate on gene expression in endocrine systems related to the adverse effects of anabolic androgenic steroids","volume":"105","author":"Alsio","year":"2009","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"4812","key":"10.1016\/j.phrs.2019.104311_bib0520","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.3037703","article-title":"Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor","volume":"237","author":"Arriza","year":"1987","journal-title":"Science"},{"issue":"8618","key":"10.1016\/j.phrs.2019.104311_bib0525","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(88)90742-8","article-title":"Localisation of 11 beta-hydroxysteroid dehydrogenase--tissue specific protector of the mineralocorticoid receptor","volume":"2","author":"Edwards","year":"1988","journal-title":"Lancet"},{"issue":"4878","key":"10.1016\/j.phrs.2019.104311_bib0530","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1126\/science.2845584","article-title":"Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated","volume":"242","author":"Funder","year":"1988","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0535","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1210\/jcem-44-5-924","article-title":"Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension","volume":"44","author":"New","year":"1977","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0540","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/ng0895-394","article-title":"Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase","volume":"10","author":"Mune","year":"1995","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.phrs.2019.104311_bib0545","first-page":"3145","article-title":"Several homozygous mutations in the gene for 11 beta-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess","volume":"80","author":"Wilson","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.phrs.2019.104311_bib0550","first-page":"2263","article-title":"A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess","volume":"80","author":"Wilson","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.phrs.2019.104311_bib0555","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1210\/endo.137.12.8940344","article-title":"Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies","volume":"137","author":"Funder","year":"1996","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0560","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18051032","article-title":"Aldosterone and Mineralocorticoid Receptors-Physiology and Pathophysiology","volume":"18","author":"Funder","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"30","key":"10.1016\/j.phrs.2019.104311_bib0565","doi-asserted-by":"crossref","first-page":"28484","DOI":"10.1074\/jbc.M100374200","article-title":"The intracellular localization of the mineralocorticoid receptor is regulated by 11beta-hydroxysteroid dehydrogenase type 2","volume":"276","author":"Odermatt","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.phrs.2019.104311_bib0570","doi-asserted-by":"crossref","first-page":"9202","DOI":"10.1073\/pnas.1633591100","article-title":"Differential binding of NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal binding protein to serve as a metabolic sensor","volume":"100","author":"Fjeld","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.phrs.2019.104311_bib0575","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1210\/endo-125-2-1046","article-title":"Licorice inhibits corticosteroid 11 beta-dehydrogenase of rat kidney and liver: in vivo and in vitro studies","volume":"125","author":"Monder","year":"1989","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib0580","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.yrtph.2006.06.002","article-title":"Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin","volume":"46","author":"Isbrucker","year":"2006","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib0585","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014218","article-title":"Liquorice-induced hypokalaemia in patients treated with Yokukansan preparations: identification of the risk factors in a retrospective cohort study","volume":"7","author":"Shimada","year":"2017","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.phrs.2019.104311_bib0590","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131165","article-title":"Pharmacokinetics of Active Components of Yokukansan, a Traditional Japanese Herbal Medicine after a Single Oral Administration to Healthy Japanese Volunteers: A Cross-Over, Randomized Study","volume":"10","author":"Kitagawa","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0595","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3143\/geriatrics.48.553","article-title":"[A case of severe hypokalemia caused by a Chinese herbal remedy (Yokukansan) in an 81-year-old woman with dementia]","volume":"48","author":"Nishiyama","year":"2011","journal-title":"Nihon Ronen Igakkai Zasshi"},{"issue":"12","key":"10.1016\/j.phrs.2019.104311_bib0600","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/09513590.2018.1480713","article-title":"Pseudohyperaldosteronism due to mumijo consumption during pregnancy: a licorice-like syndrome","volume":"34","author":"Stavropoulos","year":"2018","journal-title":"Gynecol. Endocrinol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0605","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1203\/00006450-197305000-00004","article-title":"The metabolic clearance rate, blood production, interconversion and transplacental passage of cortisol and cortisone in pregnancy near term","volume":"7","author":"Beitins","year":"1973","journal-title":"Pediatr. Res."},{"issue":"2","key":"10.1016\/j.phrs.2019.104311_bib0610","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1365-2265.1997.1230939.x","article-title":"Placental 11 beta-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure","volume":"46","author":"Benediktsson","year":"1997","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"Pt 3","key":"10.1016\/j.phrs.2019.104311_bib0615","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1042\/bj3131007","article-title":"Cloning and production of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2","volume":"313","author":"Brown","year":"1996","journal-title":"Biochem. J."},{"issue":"9129","key":"10.1016\/j.phrs.2019.104311_bib0620","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0140-6736(05)60824-0","article-title":"Fetal exposure to maternal cortisol","volume":"352","author":"Gitau","year":"1998","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.phrs.2019.104311_bib0625","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/aje\/kwp272","article-title":"Maternal licorice consumption and detrimental cognitive and psychiatric outcomes in children","volume":"170","author":"Raikkonen","year":"2009","journal-title":"Am. J. Epidemiol."},{"issue":"10","key":"10.1016\/j.phrs.2019.104311_bib0630","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.psyneuen.2010.04.010","article-title":"Maternal prenatal licorice consumption alters hypothalamic-pituitary-adrenocortical axis function in children","volume":"35","author":"Raikkonen","year":"2010","journal-title":"Psychoneuroendocrinology"},{"issue":"9","key":"10.1016\/j.phrs.2019.104311_bib0635","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/aje\/kwf130","article-title":"Preterm birth and licorice consumption during pregnancy","volume":"156","author":"Strandberg","year":"2002","journal-title":"Am. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104311_bib0640","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1203\/PDR.0b013e31818d6c24","article-title":"Prematurity is related to high placental cortisol in preeclampsia","volume":"65","author":"Aufdenblatten","year":"2009","journal-title":"Pediatr. Res."},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib0645","first-page":"1313","article-title":"Decreased gene expression of 11beta-hydroxysteroid dehydrogenase type 2 and 15-hydroxyprostaglandin dehydrogenase in human placenta of patients with preeclampsia","volume":"86","author":"Schoof","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib0650","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/gut.6.6.591","article-title":"Carbenoxolone sodium in the treatment of gastric ulcer with special reference to side-effects","volume":"6","author":"Turpie","year":"1965","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2019.104311_bib0655","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bcp.2017.01.010","article-title":"Inhibition of 11beta-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole","volume":"130","author":"Beck","year":"2017","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104311_bib0660","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.beem.2014.08.008","article-title":"Mineralocorticoid substitution and monitoring in primary adrenal insufficiency","volume":"29","author":"Quinkler","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib0665","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1530\/eje.0.1510397","article-title":"Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties","volume":"151","author":"Grossmann","year":"2004","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0670","first-page":"597","article-title":"Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor","volume":"7","author":"Rupprecht","year":"1993","journal-title":"Mol. Endocrinol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104311_bib0675","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0026-895X(25)15077-3","article-title":"Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids","volume":"25","author":"Dahlberg","year":"1984","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104311_bib0680","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0022-4731(80)90264-2","article-title":"Steroid hormone receptors and pharmacology","volume":"12","author":"Raynaud","year":"1980","journal-title":"J. Steroid Biochem."},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0685","first-page":"928","article-title":"Impaired renal 11 beta-oxidation of 9 alpha-fluorocortisol: an explanation for its mineralocorticoid potency","volume":"78","author":"Oelkers","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1-2","key":"10.1016\/j.phrs.2019.104311_bib0690","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.11.027","article-title":"The 11-ketosteroid 11-ketodexamethasone is a glucocorticoid receptor agonist","volume":"214","author":"Rebuffat","year":"2004","journal-title":"Mol. Cell. Endocrinol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0695","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1210\/jcem-72-5-1060","article-title":"Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor","volume":"72","author":"Montrella-Waybill","year":"1991","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0700","first-page":"S37","article-title":"Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans","volume":"14","author":"Williamson","year":"1996","journal-title":"J. Hypertens. Suppl."},{"issue":"7","key":"10.1016\/j.phrs.2019.104311_bib0705","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00467-011-1928-4","article-title":"Glucocorticoid-induced hypertension","volume":"27","author":"Goodwin","year":"2012","journal-title":"Pediatr. Nephrol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib0710","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0960-0760(94)00168-L","article-title":"Glucocorticoids but not mineralocorticoids modulate endothelin-1 and angiotensin II binding in SHR vascular smooth muscle cells","volume":"52","author":"Provencher","year":"1995","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0715","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00004872-199405000-00003","article-title":"Increased expression of vascular angiotensin II type 1A receptor gene in glucocorticoid-induced hypertension","volume":"12","author":"Sato","year":"1994","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2019.104311_bib0720","series-title":"Federal Drug Administration, Approval of Korlym to Control Hyperglycemia in Adult Patients With Endogenous Cushing\u2019s Syndrome","year":"2012"},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib0725","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1210\/jcem-63-3-639","article-title":"Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing\u2019s syndrome","volume":"63","author":"Bertagna","year":"1986","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.phrs.2019.104311_bib0730","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1210\/jc.2014-1843","article-title":"Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing\u2019s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone","volume":"99","author":"Fleseriu","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib0735","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1530\/EJE-09-0098","article-title":"Merits and pitfalls of mifepristone in Cushing\u2019s syndrome","volume":"160","author":"Castinetti","year":"2009","journal-title":"Eur. J. Endocrinol."},{"issue":"8","key":"10.1016\/j.phrs.2019.104311_bib0740","first-page":"3568","article-title":"Successful long-term treatment of refractory Cushing\u2019s disease with high-dose mifepristone (RU 486)","volume":"86","author":"Chu","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib0745","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2019.104311_bib0750","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000314224","article-title":"Medical treatment of Cushing\u2019s syndrome: glucocorticoid receptor antagonists and mifepristone","volume":"92","author":"Castinetti","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib0755","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1053\/j.ackd.2014.10.002","article-title":"Our own worst enemy: pharmacologic mechanisms of hypertension","volume":"22","author":"Kassel","year":"2015","journal-title":"Adv. Chronic Kidney Dis."},{"issue":"12","key":"10.1016\/j.phrs.2019.104311_bib0760","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1097\/HJH.0b013e32834c465d","article-title":"Drug-related hypertension and resistance to antihypertensive treatment: a call for action","volume":"29","author":"Rossi","year":"2011","journal-title":"J. Hypertens."},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0765","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/0003-4819-121-4-199408150-00011","article-title":"Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis","volume":"121","author":"Johnson","year":"1994","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0770","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archinte.1993.00410040045007","article-title":"A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure","volume":"153","author":"Pope","year":"1993","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"10.1016\/j.phrs.2019.104311_bib0775","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0149-2918(03)90003-8","article-title":"The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents","volume":"25","author":"Armstrong","year":"2003","journal-title":"Clin. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0780","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/HJH.0b013e328325d831","article-title":"Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study","volume":"27","author":"Krum","year":"2009","journal-title":"J. Hypertens."},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0785","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0002-9343(00)00496-4","article-title":"Drug-induced hyperkalemia: old culprits and new offenders","volume":"109","author":"Perazella","year":"2000","journal-title":"Am. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2019.104311_bib0790","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1161\/01.HYP.0000136134.31846.83","article-title":"Relationship between COX-2 specific inhibitors and hypertension","volume":"44","author":"Solomon","year":"2004","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0795","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archinte.165.5.ioi50013","article-title":"Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure","volume":"165","author":"Aw","year":"2005","journal-title":"Arch. Intern. Med."},{"issue":"11","key":"10.1016\/j.phrs.2019.104311_bib0800","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00228-012-1283-9","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study","volume":"68","author":"Fournier","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104311_bib0805","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1524-6175.2003.00514.x","article-title":"The effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs","volume":"5","author":"Morgan","year":"2003","journal-title":"J. Clin. Hypertens. Greenwich (Greenwich)"},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0810","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/00004872-200205000-00037","article-title":"Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study","volume":"20","author":"Fogari","year":"2002","journal-title":"J. Hypertens."},{"issue":"2","key":"10.1016\/j.phrs.2019.104311_bib0815","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0895-7061(94)00164-7","article-title":"Assessment of blood pressure during naproxen therapy in hypertensive patients treated with nicardipine","volume":"8","author":"Klassen","year":"1995","journal-title":"Am. J. Hypertens."},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib0820","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1161\/01.CIR.94.3.483","article-title":"Prospective study of oral contraceptives and hypertension among women in the United States","volume":"94","author":"Chasan-Taber","year":"1996","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.phrs.2019.104311_bib0825","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ecl.2011.01.008","article-title":"Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies","volume":"40","author":"Boldo","year":"2011","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"2","key":"10.1016\/j.phrs.2019.104311_bib0830","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.contraception.2003.09.002","article-title":"Progestogen-only pills and high blood pressure: is there an association? A literature review","volume":"69","author":"Hussain","year":"2004","journal-title":"Contraception"},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0835","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1210\/jcem-73-4-837","article-title":"Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women","volume":"73","author":"Oelkers","year":"1991","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib0840","first-page":"1816","article-title":"Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism","volume":"80","author":"Oelkers","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2019.104311_bib0845","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1161\/01.HYP.0000232180.72752.f8","article-title":"Drospirenone: an antihypertensive in waiting","volume":"48","author":"Sica","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2019.104311_bib0850","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/OAJC.S161737","article-title":"Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database","volume":"9","author":"Madigan","year":"2018","journal-title":"Open Access J Contracept"},{"issue":"18","key":"10.1016\/j.phrs.2019.104311_bib0855","doi-asserted-by":"crossref","first-page":"E1319","DOI":"10.1503\/cmaj.110463","article-title":"Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study","volume":"183","author":"Gronich","year":"2011","journal-title":"CMAJ"},{"issue":"10","key":"10.1016\/j.phrs.2019.104311_bib0860","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1517\/14740338.2014.950654","article-title":"Hormonal contraception, thrombosis and age","volume":"13","author":"Lidegaard","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.phrs.2019.104311_bib0865","doi-asserted-by":"crossref","first-page":"f5298","DOI":"10.1136\/bmj.f5298","article-title":"Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis","volume":"347","author":"Stegeman","year":"2013","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.phrs.2019.104311_bib0870","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/1471-0528.15211","article-title":"Severely biased review of studies assessing the risk of venous thrombosis in users of drospirenone-containing oral contraceptives","volume":"125","author":"Lidegaard","year":"2018","journal-title":"BJOG"},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0875","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.contraception.2013.04.003","article-title":"Modification of 24-h ambulatory blood pressure and heart rate during contraception with the vaginal ring: a prospective study","volume":"88","author":"Cagnacci","year":"2013","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0880","doi-asserted-by":"crossref","first-page":"R498","DOI":"10.1152\/ajpregu.00182.2014","article-title":"Estrogen status and the renin angiotensin aldosterone system","volume":"307","author":"O\u2019Donnell","year":"2014","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib0885","doi-asserted-by":"crossref","first-page":"R807","DOI":"10.1152\/ajpregu.2001.280.3.R807","article-title":"Effect of oral contraceptives on the renin angiotensin system and renal function","volume":"280","author":"Kang","year":"2001","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104311_bib0890","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11906-012-0319-y","article-title":"The \"his and hers\" of the renin-angiotensin system","volume":"15","author":"Hilliard","year":"2013","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.phrs.2019.104311_bib0895","series-title":"Endocrine Hypertension, Chapter 16, Williams Textbook of Endocrinology","author":"Young","year":"2017"},{"key":"10.1016\/j.phrs.2019.104311_bib0900","series-title":"Lakhkar AD. Adrenergic Drugs. [Updated 2018 Dec 24]. In: StatPearls [Internet]. Treasure Island (FL)","author":"Farzam","year":"2018"},{"issue":"8","key":"10.1016\/j.phrs.2019.104311_bib0905","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/sj.jhh.1001869","article-title":"The impact of oral phenylpropanolamine on blood pressure: a meta-analysis and review of the literature","volume":"19","author":"Salerno","year":"2005","journal-title":"J. Hum. Hypertens."},{"issue":"15","key":"10.1016\/j.phrs.2019.104311_bib0910","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1001\/archinte.165.15.1686","article-title":"Effect of oral pseudoephedrine on blood pressure and heart rate: a meta-analysis","volume":"165","author":"Salerno","year":"2005","journal-title":"Arch. Intern. Med."},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib0915","first-page":"201","article-title":"The effects of pseudoephedrine on blood pressure in patients with controlled, uncomplicated hypertension: a randomized, double-blind, placebo-controlled trial","volume":"4","author":"Bradley","year":"1991","journal-title":"J. Am. Board Fam. Pract."},{"issue":"1","key":"10.1016\/j.phrs.2019.104311_bib0920","first-page":"22","article-title":"Does pseudoephedrine increase blood pressure in patients with controlled hypertension?","volume":"40","author":"Coates","year":"1995","journal-title":"J. Fam. Pract."},{"issue":"2","key":"10.1016\/j.phrs.2019.104311_bib0925","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00228-014-1788-5","article-title":"Increased bioavailability of phenylephrine by co-administration of acetaminophen: results of four open-label, crossover pharmacokinetic trials in healthy volunteers","volume":"71","author":"Atkinson","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104311_bib0930","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.yrtph.2018.04.008","article-title":"An open-label, randomized, four-treatment crossover study evaluating the effects of salt form, acetaminophen, and food on the pharmacokinetics of phenylephrine","volume":"95","author":"Gelotte","year":"2018","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"12","key":"10.1016\/j.phrs.2019.104311_bib0935","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJMc1313942","article-title":"Increased phenylephrine plasma levels with administration of acetaminophen","volume":"370","author":"Atkinson","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib0940","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/CIRCULATIONAHA.106.171016","volume":"113","author":"Poirier","year":"2006","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib0945","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1097\/HJH.0000000000000145","article-title":"Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity","volume":"32","author":"Jordan","year":"2014","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2019.104311_bib0950","series-title":"Committee for Medicinal Products for Human Use (CHMP), Concept Paper on the Need for Revision of the Guideline of Medical Products Used in Weight Control, EMA\/CHMP\/229823\/","author":"European Medicines Agency","year":"2012"},{"key":"10.1016\/j.phrs.2019.104311_bib0955","series-title":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), Guideline on Clinical Evaluation of Medicinal Products Used in Weight Management, EMA\/CHMP\/311805\/2014","year":"2016"},{"issue":"2-3","key":"10.1016\/j.phrs.2019.104311_bib0960","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0014-2999(02)01423-1","article-title":"The discovery and status of sibutramine as an anti-obesity drug","volume":"440","author":"Luque","year":"2002","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104311_bib0965","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.jhh.1001297","article-title":"Sibutramine and blood pressure: a therapeutic dilemma","volume":"16","author":"Bray","year":"2002","journal-title":"J. Hum. Hypertens."},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib0970","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/11584800-000000000-00000","article-title":"Cardiovascular risk-benefit profile of sibutramine","volume":"10","author":"Scheen","year":"2010","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.phrs.2019.104311_bib0975","series-title":"Questions and Answers on the Suspension of Medicines Containing Sibutramine; EMA\/808179\/2009 Rev, EMEA\/H\/A-107\/1256, August","author":"European Medicines Agency","year":"2010"},{"key":"10.1016\/j.phrs.2019.104311_bib0980","series-title":"Federal Drug Administration, FDA Drug Safety Communication: FDA Recommends Against the Continued Use of Meridia (sibutramine)","year":"2010"},{"issue":"18","key":"10.1016\/j.phrs.2019.104311_bib0985","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1161\/CIRCULATIONAHA.107.189473","volume":"117","author":"Vetter","year":"2008","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib0990","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40263-017-0410-7","article-title":"Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine","volume":"31","author":"Hennissen","year":"2017","journal-title":"CNS Drugs"},{"issue":"8","key":"10.1016\/j.phrs.2019.104311_bib0995","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph15081789","article-title":"The effect of methylphenidate and atomoxetine on heart rate and systolic blood pressure in young people and adults with attention-deficit hyperactivity disorder (ADHD): systematic review, meta-analysis, and meta-regression","volume":"15","author":"Liang","year":"2018","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.phrs.2019.104311_bib1000","series-title":"Questions and Answers on the Review of Medicines Containing Methylphenidate, Doc. Ref. EMEA\/658285\/2008","author":"European Medicines Agency","year":"2009"},{"issue":"14","key":"10.1016\/j.phrs.2019.104311_bib1005","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMp068049","article-title":"ADHD drugs and cardiovascular risk","volume":"354","author":"Nissen","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib1010","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/0269881113482532","article-title":"Amphetamine, past and present--a pharmacological and clinical perspective","volume":"27","author":"Heal","year":"2013","journal-title":"J. Psychopharmacol. (Oxford)"},{"issue":"8","key":"10.1016\/j.phrs.2019.104311_bib1015","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/11634340-000000000-00000","article-title":"Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder","volume":"26","author":"Steer","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2019.104311_bib1020","first-page":"2275","article-title":"Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells","volume":"10","author":"Sharman","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib1025","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/0269881109103113","article-title":"Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse","volume":"23","author":"Jasinski","year":"2009","journal-title":"J. Psychopharmacol. (Oxford)"},{"key":"10.1016\/j.phrs.2019.104311_bib1030","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3389\/fphar.2017.00617","article-title":"Pharmacokinetics and pharmacodynamics of lisdexamfetamine compared with D-Amphetamine in healthy subjects","volume":"8","author":"Dolder","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104311_bib1035","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jsbmb.2018.10.016","article-title":"Effects of lisdexamfetamine on plasma steroid concentrations compared with d-amphetamine in healthy subjects: a randomized, double-blind, placebo-controlled study","volume":"186","author":"Strajhar","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.phrs.2019.104311_bib1040","series-title":"(Lisdexamphetamine) Swiss Drug Prescription Information","year":"2019"},{"issue":"16","key":"10.1016\/j.phrs.2019.104311_bib1045","first-page":"e100","article-title":"[Arterial Hyper- and Hypotension associated with psychiatric medications: a risk assessment based on the summaries of product characteristics (SmPCs)]","volume":"142","author":"Freudenmann","year":"2017","journal-title":"Dtsch. Med. Wochenschr."},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib1050","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0893-133X(01)00298-6","article-title":"Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors","volume":"25","author":"Bymaster","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2019.104311_bib1055","article-title":"Serotonin and norepinephrine reuptake inhibitors","author":"Shelton","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib1060","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/archpsyc.57.5.503","article-title":"Evidence of the dual mechanisms of action of venlafaxine","volume":"57","author":"Harvey","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"10.1016\/j.phrs.2019.104311_bib1065","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1185\/03007995.2015.1020365","article-title":"Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis","volume":"31","author":"Thase","year":"2015","journal-title":"Curr. Med. Res. Opin."},{"issue":"Pt 1","key":"10.1016\/j.phrs.2019.104311_bib1070","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.clinthera.2009.07.012","article-title":"Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder","volume":"31","author":"Perry","year":"2009","journal-title":"Clin. Ther."},{"issue":"12","key":"10.1016\/j.phrs.2019.104311_bib1075","first-page":"574","article-title":"Cardiovascular safety in depressed patients: focus on venlafaxine","volume":"56","author":"Feighner","year":"1995","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2019.104311_bib1080","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0269881104042621","article-title":"Tolerability of high-dose venlafaxine in depressed patients","volume":"18","author":"Harrison","year":"2004","journal-title":"J. Psychopharmacol. (Oxford)"},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib1085","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/FJC.0b013e31804d1cce","article-title":"The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate","volume":"49","author":"Derby","year":"2007","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib1090","first-page":"106","article-title":"15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL","volume":"7","author":"Fava","year":"2005","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.phrs.2019.104311_bib1095","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00702-018-1932-y","article-title":"A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths","volume":"125","author":"Gillman","year":"2018","journal-title":"J. Neural Transm. Vienna (Vienna)"},{"key":"10.1016\/j.phrs.2019.104311_bib1100","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/0002-9149(60)90379-9","article-title":"Monoamine oxidase inhibitors in hypertension","volume":"6","author":"Maxwell","year":"1960","journal-title":"Am. J. Cardiol."},{"issue":"14","key":"10.1016\/j.phrs.2019.104311_bib1105","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJM196509302731402","article-title":"The relative efficacy of guanethidine, methyldopa and pargyline as antihypertensive agents","volume":"273","author":"Oates","year":"1965","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104311_bib1110","article-title":"Unusual presentation of pheochromocytoma: thirteen years of anxiety requiring psychiatric treatment","volume":"2018","author":"Alguire","year":"2018","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib1115","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/archinte.1979.03630430058019","article-title":"High blood pressure. A side effect of drugs, poisons, and food","volume":"139","author":"Messerli","year":"1979","journal-title":"Arch. Intern. Med."},{"issue":"15","key":"10.1016\/j.phrs.2019.104311_bib1120","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/0002-9149(92)90766-R","article-title":"Systemic hypertension associated with tricyclic antidepressant treatment in patients with panic disorder","volume":"70","author":"Louie","year":"1992","journal-title":"Am. J. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104311_bib1125","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/archinte.1995.00430050022003","article-title":"High blood pressure. A side effect of drugs, poisons, and food","volume":"155","author":"Grossman","year":"1995","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib1130","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00003495-198121030-00002","article-title":"Adverse effects of antidepressant drugs. Part 1: monoamine oxidase inhibitors and tricyclics","volume":"21","author":"Blackwell","year":"1981","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.phrs.2019.104311_bib1135","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/1756287212457114","article-title":"Mirabegron: a review of recent data and its prospects in the management of overactive bladder","volume":"4","author":"Sacco","year":"2012","journal-title":"Ther. Adv. Urol."},{"issue":"8","key":"10.1016\/j.phrs.2019.104311_bib1140","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/ijcp.12433","article-title":"Safety and tolerability of the beta3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial","volume":"68","author":"Nitti","year":"2014","journal-title":"Int. J. Clin. Pract."},{"issue":"12","key":"10.1016\/j.phrs.2019.104311_bib1145","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/jcph.952","article-title":"An exploratory study in healthy male subjects of the mechanism of mirabegron-induced cardiovascular effects","volume":"57","author":"van Gelderen","year":"2017","journal-title":"J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.phrs.2019.104311_bib1150","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"Williams","year":"2018","journal-title":"J. Hypertens."},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib1155","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1530\/EJE-13-0882","article-title":"Diagnosis of endocrine disease: biochemical diagnosis of phaeochromocytoma and paraganglioma","volume":"170","author":"van Berkel","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.phrs.2019.104311_bib1160","doi-asserted-by":"crossref","DOI":"10.1161\/HYP.0000000000000087","article-title":"Measurement of blood pressure in humans: a scientific statement from the american heart association","author":"Muntner","year":"2019","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib1165","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/HJH.0b013e32834e4aed","article-title":"Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies","volume":"30","author":"Ward","year":"2012","journal-title":"J. Hypertens."},{"issue":"3","key":"10.1016\/j.phrs.2019.104311_bib1170","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1111\/j.1755-5922.2010.00258.x","article-title":"Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","volume":"30","author":"Raebel","year":"2012","journal-title":"Cardiovasc. Ther."},{"issue":"9","key":"10.1016\/j.phrs.2019.104311_bib1175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184402","article-title":"Incidence of and risk factors for newly diagnosed hyperkalemia after hospital discharge in non-dialysis-dependent CKD patients treated with RAS inhibitors","volume":"12","author":"Saito","year":"2017","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.phrs.2019.104311_bib1180","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s40265-018-0991-6","article-title":"Sodium zirconium cyclosilicate: a review in hyperkalaemia","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819304311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819304311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:03:52Z","timestamp":1760911432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819304311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":236,"alternative-id":["S1043661819304311"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104311","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced endocrine blood pressure elevation","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104311"}}